Scholarlink

Background <p>Older adults are under-represented in clinical trials investigating spondyloarthritis (SpA), limiting the generalizability of efficacy and safety data for this population. In this context, real-world evidence on drug retention and treatment discontinuation is essential to guide long-term therapeutic decisions, particularly for biologic disease-modifying antirheumatic drugs (bDMARDs) and apremilast.</p> Objectives <p>This study aimed to assess the 24-month retention rates of bDMARDs and apremilast in patients aged ≥&#xa0;60 years with SpA.</p> Methods <p>This was a single-center, observational study conducted over 24 months at Azienda Ospedaliero-Universitaria Policlinico “Gaspare Rodolico - San Marco” Catania. Patients aged ≥&#xa0;60 years with SpA, classified according to the&#xa0;Assessment of Spondyloarthritis International Society (ASAS) or the ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria, were included if they initiated bDMARD or apremilast therapy during the study period. The primary outcome was bDMARD and apremilast retention at 6, 12, and 24 months. Kaplan-Meier survival analysis was used to assess drug retention, and reasons for discontinuation were analyzed.</p> Results <p>A total of 100 patients (66% female; mean age 64.17&#xa0;±&#xa0;0.48 years) were included. Retention rates declined progressively, with 42% remaining on their initial therapy at 24 months. The most common reasons for discontinuation were adverse events (48%) and lack of efficacy (35%). Interleukin-17 (IL-17) inhibitors, particularly secukinumab, demonstrated superior retention compared with TNF-α inhibitors in patients with prior biologic failures.</p> Conclusions <p>Retention of bDMARDs and apremilast in older SpA patients declines over time, with adverse events and inefficacy as key discontinuation drivers. IL-17 inhibitors exhibited better retention, suggesting a potential advantage in this population. Given the impact of comorbidities and treatment safety, personalized treatment strategies and further real-world studies are needed to optimize care in older SpA patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Retention Rates of Biological Drugs in Spondyloarthritis: A 24-Month Observational Study in Patients Aged 60 Years or Older

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月13日

查看全文
  • Roberta Foti,
  • Francesco De Lucia,
  • Giorgio Amato,
  • Elisa Visalli,
  • Ylenia Dal Bosco,
  • Fabio Aiello,
  • Maria Gabriella Paolì,
  • Giambattista Privitera,
  • Angelo Montana,
  • Rosario Foti

摘要

Background

Older adults are under-represented in clinical trials investigating spondyloarthritis (SpA), limiting the generalizability of efficacy and safety data for this population. In this context, real-world evidence on drug retention and treatment discontinuation is essential to guide long-term therapeutic decisions, particularly for biologic disease-modifying antirheumatic drugs (bDMARDs) and apremilast.

Objectives

This study aimed to assess the 24-month retention rates of bDMARDs and apremilast in patients aged ≥ 60 years with SpA.

Methods

This was a single-center, observational study conducted over 24 months at Azienda Ospedaliero-Universitaria Policlinico “Gaspare Rodolico - San Marco” Catania. Patients aged ≥ 60 years with SpA, classified according to the Assessment of Spondyloarthritis International Society (ASAS) or the ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria, were included if they initiated bDMARD or apremilast therapy during the study period. The primary outcome was bDMARD and apremilast retention at 6, 12, and 24 months. Kaplan-Meier survival analysis was used to assess drug retention, and reasons for discontinuation were analyzed.

Results

A total of 100 patients (66% female; mean age 64.17 ± 0.48 years) were included. Retention rates declined progressively, with 42% remaining on their initial therapy at 24 months. The most common reasons for discontinuation were adverse events (48%) and lack of efficacy (35%). Interleukin-17 (IL-17) inhibitors, particularly secukinumab, demonstrated superior retention compared with TNF-α inhibitors in patients with prior biologic failures.

Conclusions

Retention of bDMARDs and apremilast in older SpA patients declines over time, with adverse events and inefficacy as key discontinuation drivers. IL-17 inhibitors exhibited better retention, suggesting a potential advantage in this population. Given the impact of comorbidities and treatment safety, personalized treatment strategies and further real-world studies are needed to optimize care in older SpA patients.